- Carsten Linnemann
- Dr Ton Schumacher
Dr Carsten Linnemann
- % Shareholding
- Number of employees
- Raised (Syncona co-led) from a Series A financing in 2020
Unless stated all financials at 30 June 2021
Neogene is developing a process to manufacture a wholly personalised autologous product employing engineered neoantigen-specific T cells.
Neogene, a Netherlands based company, was founded in 2018, based on the work of Dr Ton Schumacher, a leading cancer immunologist, and Dr Carsten Linnemann who was previously associate director of next generation T cell therapy at Kite Pharma. In 2020 Syncona co-led the $110m Series A financing round, committing $19m.
The company’s engineered T cells target mutated proteins, or neo-antigens, found in cancer cells as a consequence of cancer-associated DNA mutations. Neo-antigens render tumor cells vulnerable to detection by T cells. Neogene’s proprietary technology platform aims to identify TCR genes with specificity for neo-antigens from tumor biopsies. Neogene’s novel approach intends to deliver a tailored set of TCR genes for each individual patient, which will be engineered into patient-derived T cells directing them toward neo-antigens in tumor cells, with the goal of providing a fully personalized engineered T cell therapy for cancer.
- The company is developing an engineered T Cell Receptor (TCR) therapeutic approach for solid tumours based on a patient’s own neoantigens (personalised autologous cell therapy)
Unmet medical need
- Limited treatment options for patients with advanced solid tumours that have progressed through first line therapies.
- The company has not yet announced its target indications within the solid tumour field
- Complex manufacturing
- Complex early stage technology
- Highly competitive field